Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation; NUV-569, a differentiated oral small molecule selective inhibitor of the Wee1 kinase for DNA damage repair; NUV-1182, an adenosine receptor inhibitor; and drug-drug conjugate (DDC) platform that focuses on targeting an inhibitor of poly ADP ribose polymerase (PARP) to anti-cancer warheads of existing drugs, as well as PARP inhibitor to address ER+ breast and ovarian cancer. The company was formerly known as RePharmation Inc. and changed its name to Nuvation Bio Inc. in April 2019. Nuvation Bio Inc. was founded in 2018 and is headquartered in New York, New York.
Revenue of Nuvation Bio Inc. (NUVB)
Revenue in 2023 (TTM): $
According to Nuvation Bio Inc.'s latest financial reports the company's current revenue (TTM) is $. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Nuvation Bio Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $ | $-222,000 | $-99,600,000 | $-75,802,000 | $-75,802,000 |
| 2022 | $ | $-484,000 | $-128,693,000 | $-104,199,000 | $-88,664,000 |
| 2021 | $ | $-368,000 | $-97,285,000 | $-86,848,000 | $-79,734,000 |
| 2020 | $ | $-103,000 | $-43,666,000 | $-41,659,000 | $-39,496,000 |
| 2019 | $ | $ | $-32,086,000 | $-33,552,000 | $-33,552,000 |
| 2018 | $ | $ | $ | $-992,000 | $-992,000 |